论文部分内容阅读
目的探究左西孟旦对慢性心功能衰竭患者T细胞功能的影响。方法 114例慢性心功能衰竭患者,根据随机数字表法分为对照组和观察组,每组57例。对照组患者给予常规抗心功能衰竭药物治疗,观察组患者在对照组基础上给予左西孟旦治疗,比较两组临床疗效、T细胞功能及血清指标、不良反应。结果观察组总有效率为89.47%,明显高于对照组的75.44%,差异具有统计学意义(P<0.05)。治疗后两组患者CD4+、CD8+、CD4+/CD8+水平均明显优于治疗前,且观察组优于对照组,差异具有统计学意义(P<0.05)。治疗后两组患者血浆N末端脑钠肽前体(NT-proBNP)、肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白T(cTnT)均明显低于治疗前,且观察组低于对照组,差异具有统计学意义(P<0.05)。两组均未见明显不良反应。结论左西孟旦能提高慢性心功能衰竭患者临床治疗效果,改善T细胞功能和血清指标,减轻心肌损伤,安全性高。
Objective To investigate the effect of levosimendan on T cell function in patients with chronic heart failure. Methods One hundred and fourteen patients with chronic heart failure were divided into control group and observation group according to random number table method, with 57 cases in each group. Patients in the control group were given conventional anti-heart failure drug treatment. Patients in the observation group were given levosimendan on the basis of the control group. Clinical efficacy, T-cell function, serum indexes and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 89.47%, which was significantly higher than that of the control group (75.44%), the difference was statistically significant (P <0.05). After treatment, the levels of CD4 +, CD8 + and CD4 + / CD8 + in both groups were significantly better than before treatment, and the observation group was better than the control group, the difference was statistically significant (P <0.05). Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB) and cardiac troponin T (cTnT) were significantly lower in both groups after treatment than those before treatment, In the control group, the difference was statistically significant (P <0.05). No obvious adverse reactions were found in both groups. Conclusion Levosimendan can improve the therapeutic effect of chronic heart failure patients, improve T cell function and serum indexes, relieve myocardial injury, and have high safety.